Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Sun Yat-sen University
Eli Lilly and Company
Emory University
Eli Lilly and Company
Dana-Farber Cancer Institute
Eli Lilly and Company
Columbia University
Masonic Cancer Center, University of Minnesota
University of Washington
City of Hope Medical Center
Vanderbilt-Ingram Cancer Center
Mayo Clinic
NYU Langone Health